Mofezolac | Disopain | N-22 | CAS#78967-07-4 | Cyclooxygenase-1 Selective Inhibitor

MedKoo Cat#: 328605 | Name: Mofezolac

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Mofezolac, also known as Disopain and N-22, is a cyclooxygenase-1 selective inhibitor used to treat pain, musculoskeletal pain, and arthritis.

Chemical Structure

Mofezolac

CAS#78967-07-4

Theoretical Analysis

MedKoo Cat#: 328605

Name: Mofezolac

CAS#: 78967-07-4

Chemical Formula: C19H17NO5

Exact Mass: 339.1107

Molecular Weight: 339.35

Elemental Analysis: C, 67.25; H, 5.05; N, 4.13; O, 23.57

Price and Availability

Size	Price	Availability
10mg	USD 250.00	2 Weeks
25mg	USD 460.00	2 Weeks
50mg	USD 730.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Mofezolac; Disopain; N-22; N 22; N22

IUPAC/Chemical Name

2-(3,4-bis(4-methoxyphenyl)isoxazol-5-yl)acetic acid

InChi Key

DJEIHHYCDCTAAH-UHFFFAOYSA-N

InChi Code

InChI=1S/C19H17NO5/c1-23-14-7-3-12(4-8-14)18-16(11-17(21)22)25-20-19(18)13-5-9-15(24-2)10-6-13/h3-10H,11H2,1-2H3,(H,21,22)

SMILES Code

O=C(O)CC1=C(C2=CC=C(OC)C=C2)C(C3=CC=C(OC)C=C3)=NO1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 339.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Miao L, Shiraishi R, Fujise T, Kuroki T, Kakimoto T, Sakata Y, Takashima T, Iwakiri R, Fujimoto K, Shi R, Li X. Chemopreventive effect of mofezolac on beef tallow diet/azoxymethane-induced colon carcinogenesis in rats. Hepatogastroenterology. 2011 Jan-Feb;58(105):81-8. PubMed PMID: 21510291. 2: Ono N, Yamamoto N, Sunami A, Yamasaki Y, Miyake H. [Pharmacological profile of mofezolac, a new non-steroidal analgesic anti-inflammatory drug]. Nihon Yakurigaku Zasshi. 1990 Feb;95(2):63-81. Japanese. PubMed PMID: 2109726. 3: Niho N, Kitamura T, Takahashi M, Mutoh M, Sato H, Matsuura M, Sugimura T, Wakabayashi K. Suppression of azoxymethane-induced colon cancer development in rats by a cyclooxygenase-1 selective inhibitor, mofezolac. Cancer Sci. 2006 Oct;97(10):1011-4. PubMed PMID: 16984374. 4: Goto K, Ochi H, Yasunaga Y, Matsuyuki H, Imayoshi T, Kusuhara H, Okumoto T. Analgesic effect of mofezolac, a non-steroidal anti-inflammatory drug, against phenylquinone-induced acute pain in mice. Prostaglandins Other Lipid Mediat. 1998 Jul;56(4):245-54. PubMed PMID: 9777656. 5: Kitamura T, Kawamori T, Uchiya N, Itoh M, Noda T, Matsuura M, Sugimura T, Wakabayashi K. Inhibitory effects of mofezolac, a cyclooxygenase-1 selective inhibitor, on intestinal carcinogenesis. Carcinogenesis. 2002 Sep;23(9):1463-6. PubMed PMID: 12189188. 6: Satoh K, Furukawa H, Nasu Y, Sone H, Ichiki T, Kodama R, Kuwata M, Yamashita K. [Fifty two-week chronic oral toxicity study of mofezolac (N-22) in rats]. J Toxicol Sci. 1990 Jun;15 Suppl 2:77-109. Japanese. PubMed PMID: 2231796. 7: Takemoto M, Matsuo K, Katoh S, Yoshida R. [Antigenicity test of mofezolac (N-22)]. J Toxicol Sci. 1990 Jun;15 Suppl 2:261-8. Japanese. PubMed PMID: 2231794. 8: Ohuchida A, Furukawa A. Mutagenicity tests of mofezolac (N-22). J Toxicol Sci. 1990 Jun;15 Suppl 2:239-51. PubMed PMID: 2231792. 9: Fuchigami K, Otsuka T, Sameshima K, Matsunaga K, Kodama R, Yamakita O. [Reproductive and developmental toxicity study of mofezolac (N-22) (3)--Teratogenicity study in rabbits by oral administration]. J Toxicol Sci. 1990 Jun;15 Suppl 2:209-18. Japanese. PubMed PMID: 2231790. 10: Yamakita O, Koida M, Shinomiya M, Katayama S, Ikebuchi K, Yoshida R. [Reproductive and developmental toxicity study of mofezolac (N-22) (1)--Study by oral administration of N-22 prior to and early stages of pregnancy in rats]. J Toxicol Sci. 1990 Jun;15 Suppl 2:151-63. Japanese. PubMed PMID: 2231788.